NBIO / Nascent Biotech, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0167 Expires: August 31, 2027 Estimated average burden hours per response................. 1.50 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURI

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 10, 2025 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55299 NOTIFICATION OF LATE FILING CUSIP NUMBER 83108Q101 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tr

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact Nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-55299 NASCENT BIOTECH INC

NASCENT BIOTECH INC. 623 17th Street Suite 4 Vero Beach, FL 32960

NASCENT BIOTECH INC. 623 17th Street Suite 4 Vero Beach, FL 32960 April 4, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes, Esq. RE: Acceleration Request for Nascent Biotech Inc. Registration Statement on Form S-1 (File No. 333-277960) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities A

NASCENT BIOTECH INC. 631 US Highway 1 Suite 407 North Palm Beach, FL 33480

NASCENT BIOTECH INC. 631 US Highway 1 Suite 407 North Palm Beach, FL 33480 April 3, 2024 VIA EDGAR Office of Life Sciences Department of Corporate Finance United States Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Attn: Tyler Howes, Esq. Re: Nascent Biotech Inc. (the “Company”) Amendment No. 1 to Registration Statement on Form S-1 Filed on March 29, 2024 File No. 333-277

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Nascent Biotech Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

Registration No. 333-277960 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NASCENT BIOTECH INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 46-500

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Nascent Biotech Inc.

NASCENT BIOTECH INC. 631 US Highway 1 Suite 407 North Palm Beach, FL 33480

NASCENT BIOTECH INC. 631 US Highway 1 Suite 407 North Palm Beach, FL 33480 March 28, 2024 VIA EDGAR Office of Life Sciences Department of Corporate Finance United States Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Attn: Tyler Howes, Esq. Re: Nascent Biotech Inc. (the “Company”) Registration Statement on Form S-1 Filed on March 15, 2024 File No. 333-277960 Dear Mr. Howes

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

Registration No. 333-277960 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NASCENT BIOTECH INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 46-500

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NASCENT BIOTECH INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 46-5001940 (I.R.S. Employer Identification Number) 623

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Nascent Biotech Inc.

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact

JOINT FILING AGREEMENT

EX-99.1 2 tm246129d2ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the equity securities of Nascent Biotech, Inc. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgat

NBIO / Nascent Biotech, Inc. / YA II PN, Ltd. - SC 13G/A Passive Investment

SC 13G/A 1 tm246129d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.2 to SCHEDULE 13G Under the Securities Exchange Act of 1934 Nascent Biotech Inc. (Name of Issuer) Common Stock, with a par value $0.001 per share (Title of Class of Securities) 63108Q101 (CUSIP Number) December 31, 2023 (Date of Event, which Requires Filing of this Statemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2023 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission Fi

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 31, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 31, 2023 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission File

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact Nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55299 NOTIFICATION OF LATE FILING CUSIP NUMBER 83108Q101 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 29 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 29 2023 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-55299 NASCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-55299 NASCENT BIOTECH INC

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2023 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission File Nu

Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting

EX-99.1 2 nbioex991.htm PRESS RELEASE EXHIBIT 99.1 Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting NORTH PALM BEACH, FL, May 9, 2023 - Nascent Biotech, Inc. (OTCQB: NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space, announced today

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2023 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission File Num

NBIO / Nascent Biotech Inc / Burke Robert David - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Nascent Biotech Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 63108Q101 (CUSIP Number) Lowell Holden, CFO 631 US Hwy1 Suite 407 N Palm Beach, Fl 33408 (612) 961-5656 (Name, Address and Telephone Number of Person Authorized to Receive N

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact

Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial

EX-99.1 2 nbioex991.htm PRESS RELEASE EXHIBIT 99.1 Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial NORTH PALM BEACH, FL January 25, 2023 / - Nascent Biotech, Inc. (OTCQB: NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies that target various cancer types, announced the completion of the dosi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 25, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 25, 2023 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Commission Fil

NBIO / Nascent Biotech Inc / YA II PN, Ltd. - SC 13G/A Passive Investment

SC 13G/A 1 tm231355d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.1 to SCHEDULE 13G Under the Securities Exchange Act of 1934 Nascent Biotech Inc. (Name of Issuer) Common Stock, with a par value $0.001 per share (Title of Class of Securities) 63108Q101 (CUSIP Number) December 31, 2022 (Date of Event, which Requires Filing of this Statemen

JOINT FILING AGREEMENT

EX-99.1 2 tm231355d7ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the equity securities of Nascent Biotech, Inc. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgat

2U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

2U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exa

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 27, 2022 NASCENT BIOTECH INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-55299 45-0612715 (State or Other Jurisdiction of Incorporation) (Commission F

Convertible Debenture.

EXHIBIT 4.1 EXECUTION VERSION NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE O

NASCENT BIOTECH INC. 623 17th Street Suite 4 Vero Beach, FL 32960

NASCENT BIOTECH INC. 623 17th Street Suite 4 Vero Beach, FL 32960 September 23, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Ansart, Esq. RE: Acceleration Request for Nascent Biotech Inc. Registration Statement on Form S-1 (File No. 333-267496) Ladies and Gentlemen: Pursuant to Rule 461 under the Secu

NASCENT BIOTECH, INC. CONVERTIBLE DEBENTURE

EXHIBIT 4.1 EXECUTION VERSION NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE O

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2022 NASCENT BIOTECH INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-55299 45-0612715 (State or Other Jurisdiction of Incorporation) (Commission F

Calculation of Filing Fee Tables Form S-1 (Form Type) Nascent Biotech Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Nascent Biotech Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NASCENT BIOTECH INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 46-5001940 (I.R.S. Employer Identification Number) 623

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 30, 2022 NASCENT BIOTECH INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-55299 45-0612715 (State or Other Jurisdiction of Incorporation) (Commission Fi

Registration Rights Agreement dated September 6, 2022 by and among the Registrant and Platinum Point Capital LLC (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on September 9, 2022).

EX-10.2 5 nbioex102.htm REGISTRATION RIGHTS AGREEMENT EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 6, 2022 by and among NASCENT BIOTECH, INC., a Nevada corporation (the “Company”), and PLATINUM POINT CAPITAL LLC, a Nevada limited liability company (the “Investor”). WHEREAS: A. In connection with the Securities Purchase Agre

Warrant for 250,000 shares of the Company’s common stock issued to Platinum Point Capital Ltd. (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on September 9, 2022)

EXHIBIT 4.2 WARRANT THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED

Convertible Debenture issued by the Company to Platinum Point Capital LLC (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on September 9, 2022)

EXHIBIT 4.1 NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXC

Common Stock Purchase Agreement dated September 6, 2022 by and among the Registrant and Platinum Point Capital LLC (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on September 9, 2022).

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of September 6, 2022, is between NASCENT BIOTECH, INC., a company incorporated under the laws of the State of Nevada, with principal executive offices located at 623 17th Street Suite 4, Vero Beach, Florida 32960 (the ?Company?), and each of the investors listed on the Schedule of Buyers atta

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 9, 2022 NASCENT BIOTECH INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-55299 45-0612715 (State or Other Jurisdiction of Incorporation) (Commission Fi

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 30, 2022 NASCENT BIOTECH INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-55299 45-0612715 (State or Other Jurisdiction of Incorporation) (Commission Fi

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 30, 2022 NASCENT BIOTECH INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-55299 45-0612715 (State or Other Jurisdiction of Incorporation) (Commission File

Warrant for 750,000 shares of the Company’s common stock issued to YA II PN, LTD. (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on September 2, 2022)

EXHIBIT 4.2 EXECUTION VERSION WARRANT THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT O

Convertible Debenture (incorporated by reference to Exhibit 4.1 to the registrant’s Current Report on Form 8-K filed with the Commission on September 2, 2022).

EXHIBIT 4.1 EXECUTION VERSION NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE O

Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on September 2, 2022).

EXHIBIT 10.2 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of August 30, 2022 by and among NASCENT BIOTECH, INC., a Nevada corporation (the ?Company?), and YA II PN, Ltd., a Cayman Islands exempt limited partnership (the ?Investor?). WHEREAS: A. In connection with the Securities Purchase Agreement by and among the parties hereto of

Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on September 2, 2022).

EXHIBIT 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of August 30, 2022, is between NASCENT BIOTECH, INC., a company incorporated under the laws of the State of Nevada, with principal executive offices located at 623 17th Street Suite 4, Vero Beach, Florida 32960 (the ?Company?), and each of the investors listed on the Schedul

NBIO / Nascent Biotech Inc / YA II PN, Ltd. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Nascent Biotech, Inc. (Name of Issuer) Common Stock, with a par value $0.001 per share (Title of Class of Securities) 63108Q101 (CUSIP Number) August 30, 2022 (Date of Event, which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the equity securities of Nascent Biotech, Inc. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934

As filed with the Securities and Exchange Commission on August 30, 2022

As filed with the Securities and Exchange Commission on August 30, 2022 Registration No.

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact Nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-55299 NASCENT BIOTECH INC

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2021 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission File

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact Nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-55299 NASCENT BIOTECH INC

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-55299 Notification of Late Filing

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-55299 Notification of Late Filing (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on F

NBIO / Nascent Biotech Inc / Lorio Sidney J Jr - SC 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. ) Nascent Biotech Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 63108Q101 (CUSIP Number) May 28, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2021 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission File Nu

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 31, 2021 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission File

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 20, 2021 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission File

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 2, 2021 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission File

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 22, 2021 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission File

Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer

EXHIBIT 99.1 Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer SAN DIEGO, CA, March 24, 2021 ? Nascent Biotech, Inc. (OTC:NBIO) (?Nascent Biotech?, ?Nascent?, or the ?Company?), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infecti

Quarterly Report - FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact

-

NASCENT BIOTECH INC 6330 Nancy Ridge Dr./ Suite 105 San Diego, CA 92127 January 13, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Don Field RE: Acceleration Request for Nascent Biotech Inc. Registration Statement on Form S-1 (File No. 333-251525) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities

Certificate of Designation for Series A Convertible Preferred Stock*

EXHIBIT 3.1 (iii)

- FORM S-1/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NASCENT BIOTECH INC. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 46-5001940 (I.R.S. Employer Identificati

Stock purchase agreement *

EXHIBIT 10.4 Confidential Private Placement Subscription Agreement Regulation D 6330 Nancy Ridge Drive Suite 105 San Diego CA 92127 Nascent Biotech Inc. $1,000,000 1,000,000 Shares of Series A Preferred Convertible $1.00 per Share 7% Cumulative Interest 5,000,000 Warrants Minimum Investment: $50,000 PRIVATE PLACEMENT SUBSCRIPTION Regulation D Nascent Biotech Inc. 6330 Nancy Ridge Drive Suite 105 S

Certificate of Designation for Series A Convertible Preferred Stock*

EXHIBIT 3.1 (iii)

Stock purchase agreement*

EXHIBIT 10.4 Confidential Private Placement Subscription Agreement Regulation D 6330 Nancy Ridge Drive Suite 105 San Diego CA 92127 Nascent Biotech Inc. $1,000,000 1,000,000 Shares of Series A Preferred Convertible $1.00 per Share 7% Cumulative Interest 5,000,000 Warrants Minimum Investment: $50,000 PRIVATE PLACEMENT SUBSCRIPTION Regulation D Nascent Biotech Inc. 6330 Nancy Ridge Drive Suite 105 S

- FORM S-1/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NASCENT BIOTECH INC. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 46-5001940 (I.R.S. Employer Identificati

Certificate of Designation for Series A Convertible Preferred Stock*

EX-3.1 2 nbioex31.htm CERTIFICATE OF DESIGNATION EXHIBIT 3.1 (iii)

Registration Statement - FORM S-1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NASCENT BIOTECH INC. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 46-5001940 (I.R.S. Employer Identification Number) 6330

- FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 7, 2020 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission Fil

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exac

- FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2020 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission Fil

- FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 22, 2020 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission F

Quarterly Report - FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact Nam

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 13, 2020 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission File N

Annual Report - FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55299 NASCENT BIOTECH INC. (Exact

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2020 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission File Nu

Research Collaboration Agreement between Nascent Biotech Inc. and Manhattan BioSolutions, Inc. dated April 30, 2020

EX-10.1 2 nbioex101.htm RESEARCH COLLABORATION AGREEMENT EXHIBIT 10.1 RESEARCH COLLABORATION AGREEMENT This Agreement is entered into as of April 30, 2020 (the “Effective Date”) between Nascent Biotech Inc., a Nevada corporation (“NBIO”) with its principal office located at 6330 Nancy Ridge Dr Suite 105, San Diego, CA 92121, and Manhattan BioSolutions, Inc. a Delaware corporation (“MBS”) with its

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 22, 2020 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 46-5001940 (State or other jurisdiction of incorporation) (Commission File

- POS AM

As filed with the Securities and Exchange Commission on April 27, 2020 Registration No.

NBIO / Nascent Biotech Inc. S-8 POS - - FORM S-8 POS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8/Amendment 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NASCENT BIOTECH INC. (Exact name of registrant as specified in its charter) Nevada 45-0612715 (State of Incorporation) (I.R.S. Employer ID No.) 6330 Nancy Ridge Dr. Suite 105, San Diego CA 92121 (Address of Principal Executive Offices) (Zip Code) 1-61

Nascent Biotech Inc. Stock Plan as adopted by the Board of Directors on March 6, 2020.*

EX-4.3 2 nbioex43.htm STOCK PLAN EXHIBIT 4.03 NASCENT BIOTECH. STOCK PLAN (as adopted by the Board of Directors on March 6, 2020) SECTION 1. INTRODUCTION 1.1 Establishment. Effective as provided in Section 17, Nascent Biotech Inc., a Nevada corporation (the “Company”), hereby establishes this plan of stock- based compensation incentives for selected Eligible Participants of the Company or any Affi

Nascent Biotech Inc. Stock Plan as adopted by the Board of Directors on April 26, 2019.*

EX-4.3 2 nbioex43.htm STOCK PLAN EXHIBIT 4.03 NASCENT BIOTECH. STOCK PLAN (as adopted by the Board of Directors on March 6, 2020) SECTION 1. INTRODUCTION 1.1 Establishment. Effective as provided in Section 17, Nascent Biotech Inc., a Nevada corporation (the “Company”), hereby establishes this plan of stock- based compensation incentives for selected Eligible Participants of the Company or any Affi

NBIO / Nascent Biotech Inc. S-8 - - FORM S-8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NASCENT BIOTECH INC. (Exact name of registrant as specified in its charter) Nevada 45-0612715 (State of Incorporation) (I.R.S. Employer ID No.) 6330 Nancy Ridge Dr. Suite 105, San Diego CA 92121 (Address of Principal Executive Offices) (Zip Code) 1-612-916-5656 R

Nascent Biotech Investigation Drug Product, Pritumumab, to be Studied as a Potential Therapeutic agent against (Coronavirus) Covid-19

EXHIBIT 99.1 Nascent Biotech Investigation Drug Product, Pritumumab, to be Studied as a Potential Therapeutic agent against (Coronavirus) Covid-19 March 3, 2020 San Diego, CA USA. - Nascent Biotech, Inc. (OTCQB: NBIO) , today announced its intention to begin research on a possible treatment for patients infected with the Coronavirus. An article in The Journal of Biological Medicine ( Yu et al. Jou

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 5, 2020 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Commission File N

NBIO / Nascent Biotech Inc. 10-Q - Quarterly Report - FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 10, 2019 NASCENT BIOTECH, INC.

Letter from Malone Bailey

EXHIBIT 16.1 December 10, 2019 U.S. Securities and Exchange Commission 450 Fifth Street, N.W. Washington, DC 20549 RE: Nascent Biotech, Inc. File No.: 000-55399 We have read the statements under Item 4.01 of the Current Report on Form 8-K to be filed with the Securities and Exchange Commission on December 10, 2019 regarding the change of auditors. We agree with all statements pertaining to us. We

NBIO / Nascent Biotech Inc. 10-Q - Quarterly Report - FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exac

NBIO / Nascent Biotech Inc. NT 10-Q - - NT 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-55299 Notification of Late Filing (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR For Period Ended: September 30, 2019 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report

NBIO / Nascent Biotech Inc. CORRESP - -

NASCENT BIOTECH INC 6330 Nancy Ridge Dr./ Suite 105 San Diego, CA 92127 October 28, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Don Field RE: Acceleration Request for Nascent Biotech Inc. Registration Statement on Form S-1 (File No. 333-233834) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1/A (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1/A (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NASCENT BIOTECH INC. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 45-0612715 (I.R.S. Employer Identif

Certificate of Designation for Series A Convertible Preferred Stock*

EXHIBIT 3.1(iii)

NASCENT BIOTECH INC. 6300 Nancy Ridge Drive Suite 105 San Diego, CA 92121 October 14, 2019

NASCENT BIOTECH INC. 6300 Nancy Ridge Drive Suite 105 San Diego, CA 92121 October 14, 2019 VIA EDGAR Office of Healthcare & Insurance United States Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Attn: Donald Field, Esq. Re: Nascent Biotech Inc. (the ?Company?) Registration Statement on Form S-1 Filed on September 19, 2019 File No. 333-233834 Dear Mr. Field: In response to

NBIO / Nascent Biotech Inc. S-1 - Registration Statement - FORM S-1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NASCENT BIOTECH INC. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 45-0612715 (I.R.S. Employer Identification Number) 6330

Certificate of Designation for Series A Convertible Preferred Stock*

EXHIBIT 3.1(iii)

Registration Rights Agreement dated August 28, 2019 by and among the Registrant and Triton Funds, LP (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed with the Commission on September 6, 2019)

EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”), dated as of August 28, 2019 (the “Execution Date”), is entered into by and between Nascent Biotech Inc., a Nevada corporation (the “Company”), and TRITON FUNDS LP, a Delaware limited liability company (the “Investor”). RECITALS: WHEREAS, pursuant to the Common Stock Purchase Agreement entered into by a

Common Stock Purchase Agreement dated August 28, 2019 by and among the Registrant and Triton Funds, LP (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on September 6, 2019).

EXHIBIT 10.1 COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (the “Agreement”), dated as of August 28, 2019 (the “Execution Date”), is entered into by and between Nascent Biotech Inc., a Nevada corporation (the “Company”), and TRITON FUNDS LP, a Delaware limited partnership (the “Investor”). The Company and the Investor are individually referred to as a “Party” and collectivel

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 28, 2019 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Commission File

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2019 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Commission File

NBIO / Nascent Biotech Inc. 10-Q - Quarterly Report - FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact Nam

NBIO / Nascent Biotech Inc. 10-K - Annual Report - FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-55299 NASCENT BIOTECH INC

NBIO / Nascent Biotech Inc. NT 10-K - - NT 10-K

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-55299 Notification of Late Filing (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR For Period Ended: March 31, 2019 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on F

NBIO / Nascent Biotech Inc. FORM 10-Q (Quarterly Report)

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 10, 2018 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Commission Fi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 5, 2018 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Commission Fil

NBIO / Nascent Biotech Inc. FORM 10-Q (Quarterly Report)

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exac

NBIO / Nascent Biotech Inc. FORM 10-Q (Quarterly Report)

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact Nam

NBIO / Nascent Biotech Inc. FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55299 NASCENT BIOTECH INC. (Exact

NBIO / Nascent Biotech Inc. FORM 10-Q (Quarterly Report)

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact

NBIO / Nascent Biotech Inc. FORM 8-K (Current Report)

nbio8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 25, 2018 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Com

NASCENT BIOTECH UPLISTS TO THE OTC QB MARKETS

nbioex991.htm EXHIBIT 99.1 Press Release NASCENT BIOTECH UPLISTS TO THE OTC QB MARKETS Vero Beach, FL January 25, 2018 ? Nascent Biotech, Inc. (OTC: NBIO) up listed to the OTC QB effective January 25, 2018. Nascent CFO Mr. Lowell Holden stated, ?Because we have been a transparent and fully reporting company since our inception, it makes good business sense to up-list to the QB and take advantage o

NBIO / Nascent Biotech Inc. FORM 10-Q (Quarterly Report)

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exac

Nascent Biotech FORM 8-K (Current Report/Significant Event)

nbio8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2017 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Com

Nascent Biotech Announces the Completion of $1,451,000 Private Equity Raise.

nbioex991.htm EXHIBIT 99i Nascent Biotech Announces the Completion of $1,451,000 Private Equity Raise. Thursday November 2, 2017 Dateline: Vero Beach, FL, USA Vero Beach, FL, USA. - Nascent Biotech, Inc. (OTC: NBIO), today announced the completion of a $1,451,000 in private equity raises consisting of a combination of common stock and warrants. The first tranche of $305,000 closed in February 2017

Nascent Biotech FORM 8-K (Current Report/Significant Event)

nbio8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 6, 2017 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Comm

Nascent Biotech Engages HRA Capital to Raise Funds

nbioex99i.htm EXHIBIT 99i Nascent Biotech Engages HRA Capital to Raise Funds Vero Beach, FL August 9th, 2017 ? Nascent Biotech, Inc. (OTC: NBIO) has engaged HRA Capital to assist the Company in raising the necessary capital to fund the continual development of Nascent?s primary asset, Pritumumab through its phase I and II clinical trials. Nascent CEO, Sean Carrick stated, ?We are excited with this

Nascent Biotech FORM 8-K (Current Report/Significant Event)

nbio8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 9, 2017 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Commi

NBIO / Nascent Biotech Inc. FORM 10-Q (Quarterly Report)

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact Nam

NBIO / Nascent Biotech Inc. FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2017 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55299 NASCENT BIOTECH INC. (Exact

Nascent Biotech Announces IND Application Filing for Treatment of Brain Cancer.

nbioex99i.htm EXHIBIT 99(i) Nascent Biotech Announces IND Application Filing for Treatment of Brain Cancer. Pritumumab to be studied on patients suffering from Primary or Metastatic Brain Cancer. Wednesday, April 5, 2017 8:30 am EDT Dateline:Vero Beach, FL, USA Vero Beach, FL, USA. - Nascent Biotech, Inc. (OTC: NBIO), today announced the filing of its Investigational New Drug (IND) Application for

Current Report

nbio8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 5, 2017 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Commis

Nascent Biotech FORM 10-Q (Quarterly Report)

nbio10q.htm U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTEC

Nascent Biotech FORM 8-K (Current Report/Significant Event)

nbio8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 11, 2016 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Co

NASCENT BIOTECH INC ANNOUNCES ITS SECOND QUARTER RESULTS

nbioex991.htm EXHIBIT 99.1 NASCENT BIOTECH INC ANNOUNCES ITS SECOND QUARTER RESULTS Vero Beach, FL, November 11, 2016 – Nascent Biotech, Inc, (“Nascent” or “the Company”) (BB: NBIO) is pleased to announce it second quarter results as reported in the 10-Q filed on November 9, 2016. Revenue for the six months ended September 30, 2016 was $3,000,000 resulting from the previously announced license agr

Nascent Biotech FORM 10-Q (Quarterly Report)

nbio10q.htm U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTE

Nascent Biotech FORM 10-Q (Quarterly Report)

nbio10q.htm U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH IN

Nascent Biotech FORM 8-K (Current Report/Significant Event)

nbio8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 6, 2016 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Commiss

EX-10.3

nbio103.htm EXHIBIT 10.3

Nascent Biotech and Hisun Announce an Exclusive License Agreement for the Development and Commercialization of Nascent's Primary Asset, Pritumumab, in Mainland China.

nbio991.htm EXHIBIT 99.1 Nascent Biotech and Hisun Announce an Exclusive License Agreement for the Development and Commercialization of Nascent's Primary Asset, Pritumumab, in Mainland China. Development planned for multiple Epithelial Cancer Types, starting with brain cancer, in Mainland China. July 18, 2016 10:23 am EDT Dateline: TAIZHOU, Zhejiang Province, China & Vero Beach, FL, USA Public Com

Nascent Biotech FORM 10-K (Annual Report)

nbio10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2016 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [] to [] Commission file number 000-55299 NASCENT B

Nascent Biotech NT 10-K

nbiont10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transiti

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

nbio8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 4, 2016 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Commis

Nascent Biotech FORM 10-Q (Quarterly Report)

nbio10q.htm U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTEC

Nascent Biotech NT 10-Q

nbiont10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Trans

Nascent Biotech FORM 8-K (Current Report/Significant Event)

nbio8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 1, 2015 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Co

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exac

Nascent Biotech FORM 8-K (Current Report/Significant Event)

nbio8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 21, 2015 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (C

NASCENT BIOTECH INC ANNOUNCES AN AGREEMENT REDUCING ITS LIABILITIES BY $1.4 MILLION

nbioex99(i).htm EXHIBIT 99(i) NASCENT BIOTECH INC ANNOUNCES AN AGREEMENT REDUCING ITS LIABILITIES BY $1.4 MILLION San Diego, CA September 22, 2015 ? Nascent Biotech, Inc. (?Nascent? or ?the Company?) (PINK.BB: NBIO), reached an agreement with the licensor whereby the licensor will receive cash payments totaling $63,000 and 200,000 shares of the Company?s common stock plus a 1% royalty of net sales

Other Events

nbio8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 16, 2015 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (C

Bylaws (incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K filed September 8, 2015).

nbioex3ii.htm

Nascent Biotech FORM 8-K (Current Report/Significant Event)

nbio8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 8, 2015 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (Co

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC (Exact Nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2015 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55299 NASCENT BIOTECH INC. (Exact

Nascent Biotech NT 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on F

Nascent Biotech FORM 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2015 NASCENT BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55299 45-0612715 (State or other jurisdiction of incorporation) (CommissionFile Nu

Nascent Biotech ESP

March 5, 2015 VIA EMAIL Jeffrey P. Riedler Assistant Director United States Securities and ExchangeCommission Washington, D.C. 20549 Re: Nascent Biotech Inc. Registration Statement on Form 10-12G Amendment Filed January 2, 2015 File No. 000-55299 Dear Mr. Riedler: In response to your letter of January 30, 2015 regarding the above-referenced issuer, Nascent Biotech, Inc. (the "Company"), please be

Nascent Biotech 10-12G/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10/A (Amendment No. 2) GENERAL FORM FOR THE REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 NASCENT BIOTECH INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-55299 45-0612715 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

LICENSE AGREEMENT

EXHIBIT 10.2 LICENSE AGREEMENT This LICENSE AGREEMENT (?Agreement?) is entered into and made effective as of the 6th day of July, 2009 (?Effective Date?) by and between Nascent Biologics, Inc., a Delaware corporation (?Licensee?), and Hideaki Hagiwara and Hagiwara Institute of Health Integrated Medical Sciences Association Foundation, a 501(c)(3) non-profit corporation (?HIHIMSA Foundation? and, t

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55299 NASCENT BIOTECH INC. (Exac

EXCHANGE AGREEMENT BY AND AMONG JIN-EN INTERNATIONAL GROUP HOLDING COMPANY, NASCENT BIOTECH, INC. CERTAIN STOCKHOLDERS OF EACH Dated July 15, 2014

EXHIBIT 10.1 EXCHANGE AGREEMENT BY AND AMONG JIN-EN INTERNATIONAL GROUP HOLDING COMPANY, NASCENT BIOTECH, INC. AND CERTAIN STOCKHOLDERS OF EACH Dated July 15, 2014 1 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the "Agreement"), is made and entered into as of July 15, 2014, by and among Jin-En International Group Holding Company, a Nevada corporation ("JIN"), Nascent Biotech, Inc., a Nevada corpora

NBIO / Nascent Biotech Inc. 10-12G/A - - 10-12G/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10 /A (Amendment No. 1) GENERAL FORM FOR THE REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 NASCENT BIOTECH INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-55299 45-0612715 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

NBIO / Nascent Biotech Inc. CORRESP - -

January 2, 2015 VIA EMAIL Jeffrey P. Riedler Assistant Director United States Securities and Exchange Commission Washington, D.C. 20549 Re: Nascent Biotech Inc. Registration Statement on Form 10-12(g) Filed October 28, 2014 File No. 000-55299 Dear Mr. Riedler: In response to your letter of November 24, 2014 regarding the above-referenced issuer, Nascent Biotech, Inc. (the "Company"), please be adv

NBIO / Nascent Biotech Inc. CORRESP - -

December 19, 2014 VIA EMAIL Jeffrey P. Riedler Assistant Director United States Securities and Exchange Commission Washington, D.C. 20549 Re: Nascent Biotech Inc. Registration Statement on Form 10-12(g) Filed October 28, 2014 File No. 000-55299 Dear Mr. Riedler: In response to your letter of November 24, 2014 regarding the above-referenced issuer, Nascent Biotech, Inc. (the "Company"), please be a

NBIO / Nascent Biotech Inc. 10-12G - - 10-12G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10 GENERAL FORM FOR THE REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 NASCENT BIOTECH INC. (Exact Name of Registrant as Specified in its Charter) Nevada 45-0612715 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Specimen Stock Certificate (incorporated by reference to Exhibit 4.1 to the registrant’s registration statement on Form 10 filed with the Commission on October 28, 2014).

EXHIBIT 4.1

By-Laws (incorporated by reference to Exhibit 3.2 to the registrant’s registration statement on Form 10 filed with the Commission on October 28, 2014).

EXHIBIT 3.03 1 2 3 4 5 6

Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.3 to the registrant’s registration statement on Form 10 with the Commission on October 28, 2014).

EXHIBIT 3.02

EX-2.1

EXHIBIT 2.1

Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant’s registration statement on Form 10 with the Commission on October 28, 2014).

EXHIBIT 3.01